Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

View the Online Magazine

- Advertisement -

Launches

New saliva-based COVID-19 test promises results in ten minutes

A saliva-based lateral flow COVID-19 test which promises results in ten minutes has launched in the UK. The Rapid Saliva Protein Test (RSPT) from Medusa...

Private funding sees IcanoMAB launch to develop precision mAbs

IcanoMAB, a privately-funded biotech based in Germany, has launched to develop novel precision canonical antibodies for the treatment of cancer, immune-system related diseases and...

Moletest (Scotland) Ltd aims to revolutionise melanoma skin cancer screening with its new test, nomela®

British medical technology company, Moletest (Scotland) Ltd, is offering primary care professionals the opportunity to substantially reduce the number of unnecessary dermatology referrals to...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Avacta launch COVID-19 laboratory test

Avacta Group is set to launch a high-performance test for the SARS-CoV-2 spike protein to support global efforts to combat COVID-19. Enzyme linked immunosorbent assays...

US secures 100m doses of Moderna’s COVID-19 mRNA vaccine

The US government has secured 100 million doses of Moderna’s mRNA vaccine against COVID-19. The government has paid Moderna, the Cambridge, UK-based biotech pioneering mRNA...

In brief: Sanofi & GSK in talks to supply 300m doses of COVID vaccine to EU

Sanofi and GlaxoSmithKline (GSK) are in “advanced discussions” with the European Commission (EC) for the supply of up to 300 million doses of a...

Arcturus to supply Israel with COVID-19 vaccine candidate

Arcturus Therapeutics has signed an agreement to supply the its COVID-19 vaccine candidate, LUNAR-COV1D, to the Israeli Ministry of Health. Delivery of the vaccine candidate...

Approvals

FDA clears Roche’s BK virus quantitative test of cobas systems

Roche has secured US approval for the cobas BKV Test on the cobas 6800 and 8800 Systems to support better care for transplant patients. The...

FDA approves additional doses of Trulicity for type 2 diabetes

The US FDA has approved two additional doses of Eli Lilly’s Trulicity (dulaglutide) for the treatment of type 2 diabetes. The approval expands the label...

Spravato approved for use to treat MDD in Scotland

The Scottish Medicines Consortium (SMC) have accepted Spravato (esketamine) nasal spray for use within NHS Scotland less than a week after NICE ruled not...

EU approves Imfinzi for ES-SCLC

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in...

FDA fast-tracks LEO’s investigational topic cream for CHE

US regulators have this week fast-tracked LEO pharma’s delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate-to-severe...

NICE will not recommend Spravato nasal spray for MDD – Janssen responds

In second draft guidance published this week, the National Institute for Health and Care Excellence (NICE) states it will not recommend Spravato (esketamine) nasal...

Manufacturiung

Finance

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Search for new cancer treatments get £8m genetic boost

Projects to find new treatments for cancer, using whole genome sequencing, have received a £8 million funding boost from UK Research and Innovation (UKRI). Despite...

Mylan acquiring Aspen’s European thrombosis business

Mylan is expanding its complex injectables offering and presence in hospitals with the €641.9 million acquisition of Aspen Pharmacare's thrombosis business in Europe. The portfolio...

Research & Development
Latest

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Appointments

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...
- Advertisement -

EU approves Imfinzi for ES-SCLC

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in...

FDA fast-tracks LEO’s investigational topic cream for CHE

US regulators have this week fast-tracked LEO pharma’s delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate-to-severe...